Duchesnay Inc. Receives Approval of Supplemental New Drug Application (sNDA) to Add Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause, to the Indication of Osphena® (ospemifene)

BLAINVILLE, QC, Jan. 29, 2019 /PRNewswire/ - Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal...

from PR Newswire: https://prn.to/2B8l9l6